title: Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.
abstract: BACKGROUND
  Vinorelbine was added to carboplatin plus paclitaxel to determine efficacy and toxicity in non-small cell lung cancer (NSCLC) patients with good performance status.
  
  
  METHODS
  Vinorelbine 30 mg/m2 plus paclitaxel 175 mg/m2 plus carboplatin AUC 5 was administered every three weeks for a maximum of 6 cycles.
  
  
  RESULTS
  One out of 37 patients had a complete and 12 a partial remission (35% response rate). Six patients (16%) had disease stabilization and 18 (49%) progressed. Grade III or IV neutropenia occurred in 11 (30%) and febrile neutropenia in 6 (16%) patients. Grade III/IV neuropathy was observed in 6 (16%) patients. The median time to progression was 6 months (95% CI 4.0 - 8.0), and median survival 11 months (95% CI 8.3 - 13.7). One- and two-year survival was 41% (95% CI 24 - 58) and 24% (95% CI 8.7 - 39.1), respectively.
  
  
  CONCLUSIONS
  This triple-chemotherapy combination is feasible. The response rates justify further investigation in similar patient subgroups.
authors.affiliation: Department of Medicine III (Hematology, Oncology and Transfusionmedicine), University Medicine of Berlin, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. alexander.schmittel@charite.de
authors.forename: Alexander
authors.initials: A
authors.lastname: Schmittel
authors.forename: Jan Michael
authors.initials: JM
authors.lastname: Siehl
authors.forename: Manfred
authors.initials: M
authors.lastname: Schulze
authors.forename: Karsten
authors.initials: K
authors.lastname: Schulze
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Keilholz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage*; D015996:Survival Rate; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D000077235:Vinorelbine